Capitis Pharmaceuticals Private Limited
Pharmaceutical company specializing in trading pharmaceutical products.
2013 | Aurangabad, Maharashtra (India) | Active
Capitis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -1.97%
- Profit Growth 101.25%
- Ebitda 103.04%
- Net Worth 32.47%
- Total Assets -7.88%
About Capitis Pharmaceuticals
Capitis Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 March 2013 and has a history of 11 years and 11 months. Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Ganjewar and Prashant Ganjewar serve as directors at the Company.
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24305MH2013PTC241064
- Company No.
241064
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2013
- Date of AGM
30 Jun 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Capitis Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Ganjewar  | Director | 16-Mar-2013 | Current |
| Prashant Ganjewar | Director | 16-Mar-2013 | Current |
Financial Performance of Capitis Pharmaceuticals.
Capitis Pharmaceuticals Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 1.97% decrease. The company also saw a substantial improvement in profitability, with a 101.25% increase in profit. The company's net worth Soared by an impressive increase of 32.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Capitis Pharmaceuticals?
In 2019, Capitis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Capitis Pharmaceuticals?
Unlock and access historical data on people associated with Capitis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Capitis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Capitis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
